Authors:
Tschop, K
Rommel, F
Schmidkonz, P
Emmerich, B
Schulze, J
Citation: K. Tschop et al., Neuropathy after cyclophosphamide high dose chemotherapy in a Morbus Werlhof patient, DEUT MED WO, 126(12), 2001, pp. 334-334
Authors:
Mitterer, M
Lanthaler, AJ
Schnabel, B
Svaldi, M
Oduncu, F
Coser, P
Emmerich, B
Huemer, H
Straka, C
Citation: M. Mitterer et al., Peripheral blood monoclonal B-cells predict the event free survival in multiple myeloma, LEUK LYMPH, 41(3-4), 2001, pp. 387-395
Authors:
Siegmund, B
Welsch, J
Loher, F
Meinhardt, G
Emmerich, B
Endres, S
Eigler, A
Citation: B. Siegmund et al., Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptoticmembers of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis, LEUKEMIA, 15(10), 2001, pp. 1564-1571
Authors:
Hallek, M
Schmitt, B
Wilhelm, M
Busch, R
Krober, A
Fostitsch, HP
Sezer, O
Herold, M
Knauf, W
Wendtner, CM
Kuse, R
Freund, M
Franke, A
Schriever, F
Nerl, C
Dohner, H
Thiel, E
Hiddemann, W
Brittinger, G
Emmerich, B
Citation: M. Hallek et al., Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia, (CLL): results of a phase II study of the German CLL Study Group, BR J HAEM, 114(2), 2001, pp. 342-348
Authors:
Gahn, B
Brittinger, G
Dolken, G
Dohner, H
Emmerich, B
Franke, A
Freund, M
Huber, C
Kuse, R
Scholten, T
Hiddemann, W
Citation: B. Gahn et al., Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemia, LEUK LYMPH, 37(1-2), 2000, pp. 169-173
Authors:
von Bubnoff, N
Adler, S
Danhauser-Riedl, S
Kamp, T
Nerl, C
Emmerich, B
Hallek, M
Citation: N. Von Bubnoff et al., The activation of intracellular tyrosine kinases by interferon-alpha (IFN alpha) correlates with its antiproliferative activity in B-lymphoid cell lines, but not in B-cell chronic lymphocytic leukemia patients, ANN HEMATOL, 79(3), 2000, pp. 119-126
Authors:
Einsele, H
Straka, C
Emmerich, B
Bamberg, M
Budach, W
Citation: H. Einsele et al., High-dose chemotherapy with hematopoietic stem cell transplantation for patients with advanced multiple myeloma, ONKOLOGIE, 23(3), 2000, pp. 272-274
Authors:
Titzer, S
Christensen, O
Manzke, O
Tesch, H
Wolf, J
Emmerich, B
Carsten, C
Diehl, V
Bohlen, H
Citation: S. Titzer et al., Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects, BR J HAEM, 108(4), 2000, pp. 805-816
Authors:
Nolte, A
Buhmann, R
Emmerich, B
Schendel, D
Hallek, M
Citation: A. Nolte et al., Reconstitution of the cellular immune response after autologous peripheralblood stem cell transplantation in patients with non-Hodgkin's lymphoma, BR J HAEM, 108(2), 2000, pp. 415-423
Citation: B. Emmerich et M. Hallek, Recent advances in the biology and treatment of chronic lymphocytic leukemia and related diseases, J MOL MED-J, 77(2), 1999, pp. 258-258
Authors:
Wendtner, CM
Schmitt, B
Wilhelm, M
Dreger, P
Montserrat, E
Emmerich, B
Hallek, M
Citation: Cm. Wendtner et al., Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy, ANN ONCOL, 10(5), 1999, pp. 505-509
Authors:
Meinhardt, G
Roth, J
Totok, G
Auner, H
Emmerich, B
Hass, R
Citation: G. Meinhardt et al., Signaling defect in the activation of caspase-3 and PKC delta in human TURleukemia cells is associated with resistance to apoptosis, EXP CELL RE, 247(2), 1999, pp. 534-542
Authors:
Mitterer, M
Oduncu, F
Lanthaler, AJ
Drexler, E
Amaddii, G
Fabris, P
Emmerich, B
Coser, P
Straka, C
Citation: M. Mitterer et al., The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients, BR J HAEM, 106(3), 1999, pp. 737-743
Authors:
Buhmann, R
Nolte, A
Westhaus, D
Emmerich, B
Hallek, M
Citation: R. Buhmann et al., CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells, BLOOD, 93(6), 1999, pp. 1992-2002
Authors:
Hallek, M
Langenmayer, I
Nerl, C
Knauf, W
Dietzfelbinger, H
Adorf, D
Ostwald, M
Busch, R
Kuhn-Hallek, I
Thiel, E
Emmerich, B
Citation: M. Hallek et al., Elevated serum thymidine kinase levels identify a subgroup at high risk ofdisease progression in early, nonsmoldering chronic lymphocytic leukemia, BLOOD, 93(5), 1999, pp. 1732-1737